| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Conditions to maintain primary tumor cells in culture are largely unknown for most tumor entities including rhabdomyosarcoma. In this collaborative study with Dr. Beat Schäfer's laboratory, we performed DNA methylation profiles of rhabdomyosarcoma patient-derived xenograft (PDX) and their matching PDX-derived primary cells (PPC), where the PPCs were developed and maintained under optimized culture conditions. We further compared DNA methylation profiles between these PDXs and PPCs. Exome sequencing and copy number analysis between these rhabdomyosarcoma PDXs and PPXs were also carried out. These analyses may help us to evaluate a feasibility of in vitro profiling of primary rhabdomyosarcoma cells from a genomic perspective.
- Study Design:
- Case Set
- Study Type:
- Case Set
- Total number of consented subjects: 39
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
We included a total of 19 pairs of rhabdomyosarcoma PDX and 20 PDX-derived primary cells. No specific exclusion criteria were employed.
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment DNA Methylation Array Illumina Infinium MethylationEPIC N/A N/A DNA Methylation Array Illumina BeadArray N/A N/A - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Rhabdomyosarcoma
- Links to Related Genes
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Frederic G. Barr, MD, PhD. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator